Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-38606
Matter-Walstra, K W; Dedes, K J; Schwenkglenks, M; Brauchli, P; Szucs, T D; Pestalozzi, B C (2010). Trastuzumab beyond progression: a cost-utility analysis. Annals of Oncology, 21(11):2161-2168.
- Registered users only
View at publisher
BACKGROUND: The continuation of trastuzumab beyond progression in combination with capecitabine as secondary chemotherapy for HER2-positive metastatic breast cancer (MBC) prolongs progression-free survival without a substantial increase in toxicity. PATIENTS AND METHODS: A Markov cohort simulation was used to follow the clinical course of typical patients with MBC. Information on response rates and major adverse effects was derived, and transition probabilities were estimated, based on the results of the Breast International Group 03-05 clinical trial. Direct costs were assessed from the perspective of the Swiss health care system. RESULTS: The addition of trastuzumab to capecitabine is estimated to cost on average an additional of €33,980 and to yield a gain of 0.35 quality-adjusted life years (QALYs), resulting in an incremental cost-effectiveness ratio of €98,329/QALYs gained. Probabilistic sensitivity analysis showed that the willingness-to-pay threshold of €60,000/QALY was reached in 12% of cases. CONCLUSION: The addition of trastuzumab to capecitabine in MBC patients is more expensive than what is typically regarded as cost-effective but falls within the value ranges found for established regimens in the treatment of MBC.
0 downloads since deposited on 27 Dec 2010
0 downloads since 12 months
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > Epidemology, Biostatistics and Prevention Institute (EBPI)
04 Faculty of Medicine > University Hospital Zurich > Clinic for Gynecology
|DDC:||610 Medicine & health|
|Deposited On:||27 Dec 2010 12:36|
|Last Modified:||10 Dec 2013 12:30|
|Publisher:||Oxford University Press|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page